Relationship between daily dose, plasma concentrations, dopamine receptor occupancy, and clinical response to quetiapine: A review

Journal of Clinical Psychiatry

Volumn 72, Issue 8, 2011, Pages 1108-1123

  Sparshatt, Anna ^a,b   Taylor, David ^a,b   Patel, Maxine X ^b   Kapur, Shitij ^b  

^a SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALIMEMAZINE; CARBAMAZEPINE; CITALOPRAM; CLOZAPINE; DOPAMINE RECEPTOR; ESCITALOPRAM; FLUVOXAMINE; LAMOTRIGINE; LEVOMEPROMAZINE; OLANZAPINE; OXAZEPAM; QUETIAPINE;

BLOOD SAMPLING; CARDIOVASCULAR DISEASE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; DRUG POTENTIATION; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MAXIMUM PLASMA CONCENTRATION; PLASMA PROTEIN BINDING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; REVIEW; SEDATION; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT RESPONSE; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; BIOLOGICAL AVAILABILITY; BIPOLAR DISORDER; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; STATISTICS AS TOPIC; YOUNG ADULT;

EID: 80052464648     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.09r05739yel     Document Type: Review

References (74)

1. Baumann P, Hiemke C, Ulrich S, et al; Arbeitsge-meinschaft fur neuropsychopharmakologie und pharmakopsychiatrie. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry. 2004;37(6):243-265. doi:10.105/s-204-832687 PubMed (Pubitemid 39587052)
2. Castberg I, Skogvoll E, Spigset O. Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service. J Clin Psychiatry. 2007;68(10):1540-1545. doi:10.408/JCP.v68n101 PubMed (Pubitemid 350073402)
3. Aichhorn W, Marksteiner J, Walch T, et al. Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations. Int Clin Psychopharmacol. 2006;21(2):81-85. doi:10.1097/01.yic.018213.467.f1 PubMed (Pubitemid 43740314)
4. Dragicevic A, Muller MJ, Sachse J, et al. Therapeutic drug monitoring (TDM) of quetiapine. Lecture presented at the Symposium of the AGNP; October 8-10, 2003; Munich, Germany.
5. Dragicevic A, Sachse J, Hartter S, et al. Serum concentrations of quetiapine and clinical effects. International Meeting on Pharmacovigilance in Psychiatry, Therapeutic Drug Monitoring and Pharmacogenetics of Psychotropic Drugs; September 1-3, 2005; Lausanne, Switzerland.
6. Guy W. The Clinical Global Impressions Scale. In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. Rev Ed. Rockville, MD: National Institute of Mental Health; 1976:157-169.
7. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU Side Effect Rating Scale: A New Comprehensive Rating Scale for Psychotropic Drugs and a Cross-Sectional Study of Side Effects in Neuroleptic-Treated Patients. Acta Psychiatr Scand suppl. 1987;76(s334):1-100. doi:10.1/j.160-047.1987.tb1056.x (Pubitemid 17115352)
8. Dragicevic A, Trotzauer D, Hiemke C, et al. Gender and age effects on quetiapine serum concentrations in patients with schizophrenia or schizoaffective disorders. Lecture presented at the 24th Symposium of the AGNP; October, 5-8; 2005. Munich, Germany.
9. Gerlach M, Hünnerkopf R, Rothenhöfer S, et al. Therapeutic drug monitoring of quetiapine in adolescents with psychotic disorders. Pharmacopsychiatry. 2007;40(2):72-76. doi:10.105/s-207-972573 PubMed (Pubitemid 46697678)
10. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10(3):799-812. doi:10.246/PR0.10.3.79-812
11. Mauri MC, Volonteri LS, Fiorentini A, et al. Two weeks? quetiapine treatment for schizophrenia, drug-induced psychosis and borderline personality disorder: a naturalistic study with drug plasma levels. Expert Opin Pharmacother. 2007;8(14):2207-2213. doi:10.1517/1465656.8.14.207 PubMed (Pubitemid 350001584)
12. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276. PubMed (Pubitemid 18039085)
13. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62. doi:10.136/jnp.23.1.56 PubMed
14. Mauri MC, Fiorentini A, Volonteri FS, et al. Quetiapine in acute psychosis and personality disorders during hospitalisation: assessment of therapeutic range. Poster presented at the World Psychiatric Association International Congress; November 10-13, 2004; Florence, Italy.
15. Hasselstrøm J, Linnet K. Quetiapine serum concentrations in psychiatric patients: The influence of comedication. Ther Drug Monit. 2004;26(5):486-491. PubMed (Pubitemid 39314315)
16. Castberg I, Spigset O. Prescribing patterns and the use of therapeutic drug monitoring of psychotropic medication in a psychiatric high-security unit. Ther Drug Monit. 2008;30(5):597-603. doi:10.1097/FTD.0b013e3181862c4 PubMed
17. Small JG, Hirsch SR, Arvanitis LA, et al; Seroquel Study Group. Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry. 1997;54(6):549-557. PubMed
18. Andreasen N. The Scale for the Assessment of Negative Symptoms (SANS): Conceptual and theoretical foundations. Br J Psychiatry suppl. 1989;155(suppl 7):49-58.
19. Li KY, Li X, Cheng ZN, et al. Multiple dose pharmacokinetics of quetiapine and some of its metabolites in Chinese suffering from schizophrenia. Acta Pharmacol Sin. 2004;25(3):390-394. PubMed (Pubitemid 38316053)
20. McConville BJ, Arvanitis LA, Thyrum PT, et al. Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders. J Clin Psychiatry. 2000;61(4):252-260. PubMed (Pubitemid 30305366)
21. Jaskiw GE, Thyrum PT, Fuller MA, et al. Pharmacokinetics of quetiapine in elderly patients with selected psychotic disorders. Clin Pharmacokinet. 2004;43(14):1025-1035. doi:10.2165/0308-2043140-05 PubMed (Pubitemid 39602016)
22. DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: An atypical antipsychotic. Clin Pharmacokinet. 2001;40(7):509-522. doi:10.2165/0308-2014070-03 PubMed
23. Gunasekara NS, Spencer CM. Quetiapine: A review of its use in schizophrenia. CNS Drugs. 1998;9(4):325-340. doi:10.2165/023210-19809040-07 (Pubitemid 28210367)
24. Winter HR, Earley WR, Hamer-Maansson JE, et al. Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders. J Child Adolesc Psychopharmacol. 2008;18(1):81-98. doi:10.1089/cap.207.084 PubMed (Pubitemid 351311245)
25. Figueroa C, Brecher M, Hamer-Maansson JE, et al. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(2):199-204. doi:10.1016/j.pnpbp.208.09.026 PubMed
26. Xiberas X, Martinot JL, Mallet L, et al. In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia. J Clin Psychopharmacol. 2001;21(2):207-214. doi:10.1097/04714-201040-013 PubMed (Pubitemid 32221059)
27. Xiberas X, Martinot JL, Mallet L, et al. Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. Br J Psychiatry. 2001;179(6):503-508. doi:10.192/bjp.179.6.503 PubMed (Pubitemid 34031674)
28. Agid O, Mamo D, Ginovart N, et al. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response - a double-blind PET study in schizophrenia. Neuropsychopharmacology. 2007;32(6):1209-1215. doi:10.1038/sj.np.1301242 PubMed (Pubitemid 46788848)
29. Kapur S, Zipursky R, Jones C, et al. A positron emission tomography study of quetiapine in schizophrenia: A preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry. 2000;57(6):553-559. doi:10.101/archpsyc.57.6.53 PubMed (Pubitemid 30349435)
30. Gefvert O, Lundberg T, Wieselgren IM, et al. D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. Eur Neuropsychopharmacol. 2001;11(2):105-110. doi:10.1016/S0924-97X(0)013-4 PubMed
31. Gefvert O, Bergström M, Långström B, et al. Time course of central nervous dopamine- D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacology (Berl). 1998;135(2):119-126. doi:10.107/s0213050492 PubMed (Pubitemid 28055494)
32. Mamo DC, Uchida H, Vitcu I, et al. Quetiapine extended-release versus immediate-release formulation: a positron emission tomography study. J Clin Psychiatry. 2008;69(1):81-86. doi:10.408/JCP.v69n01 PubMed (Pubitemid 351282000)
33. Tauscher-Wisniewski S, Kapur S, Tauscher J, et al. Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade. J Clin Psychiatry. 2002;63(11):992-997. PubMed (Pubitemid 35388057)
34. Citrome L, Jaffe A, Levine J, et al. Dosing of quetiapine in schizophrenia: How clinical practice differs from registration studies. J Clin Psychiatry. 2005;66(12):1512-1516. doi:10.408/JCP.v6n1203 PubMed (Pubitemid 43068688)
35. Pierre JM, Wirshing DA, Wirshing WC, et al. High-dose quetiapine in treatment refractory schizophrenia. Schizophr Res. 2005;73(2-3):373-375. doi:10.1016/j.schres.204.07.014 PubMed (Pubitemid 40093903)
36. Bobes J, Garcia-Portilla MP, Saiz PA, et al. High degree of tolerability for monotherapy with high doses of quetiapine: A case report. J Clin Psychiatry. 2002;63(11):1048-1049. PubMed (Pubitemid 35388070)
37. Sparshatt A, Jones S, Taylor D. Quetiapine: dose-response relationship in schizophrenia. CNS Drugs. 2008;22(1):49-68, discussion 69-72. doi:10.2165/023210-2082010-04 PubMed
38. Arvanitis LA, Miller BG. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry. 1997;42(4):233-246. doi:10.1016/S06-323(97)0190-X PubMed (Pubitemid 27325811)
39. Leucht S, Kane JM, Etschel E, et al. Linking the PANSS, BPRS, and CGI: Clinical implications. Neuropsychopharmacology. 2006;31(10):2318-2325. PubMed (Pubitemid 44413213)
40. Seeman P, Tallerico T. Rapid release of antipsychotic drugs from dopamine D2 receptors: An explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am J Psychiatry. 1999;156(6):876-884. PubMed (Pubitemid 29260342)
41. Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000;157(4):514-520. doi:10.176/api.ajp.157.4.514 PubMed (Pubitemid 30191189)
42. Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? a new hypothesis. Am J Psychiatry. 2001;158(3):360-369. doi:10.176/api.ajp.158.3.360 PubMed (Pubitemid 32205190)
43. Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet. 2003;42(2):107-121. doi:10.2165/0308-20342020-01 PubMed (Pubitemid 36188552)
44. Beierle I, Meibohm B, Derendorf H. Gender differences in pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther. 1999;37(11):529-547. PubMed (Pubitemid 29524971)
45. Mauri MC, Volonteri LS, Colasanti A, et al. Clinical pharmacokinetics of atypical antipsychotics: A critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet. 2007;46(5):359-388. doi:10.2165/0308-20746050-01 PubMed (Pubitemid 46686464)
46. Jensen NH, Rodriguiz RM, Caron MG, et al. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology. 2008;33(10):2303-2312. doi:10.1038/sj.np.1301646 PubMed
47. Tomalik-Scharte D, Lazar A, Fuhr U, et al. The clinical role of genetic polymorphisms in drug-metabolizing enzymes. Pharmacogenomics J. 2008;8(1):4-15. doi:10.1038/sj.tpj.650462 PubMed
48. Weinshilboum R. Inheritance and drug response. N Engl J Med. 2003;348(6):529-537. doi:10.1056/NEJMra02021 PubMed (Pubitemid 36159889)
49. Goldstein DB. Pharmacogenetics in the laboratory and the clinic. N Engl J Med. 2003;348(6):553-556. doi:10.1056/NEJMe020173 PubMed (Pubitemid 36159892)
50. Rau T, Wohlleben G, Wuttke H, et al. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants - A pilot study. Clin Pharmacol Ther. 2004;75(5):386-393. doi:10.1016/j.clpt.203.12.015 PubMed (Pubitemid 38534559)
51. Peters EJ, Slager SL, Kraft JB, et al. Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. PLoS ONE. 2008;3(4):e1872. doi:10.1371/journal.pone.01872 PubMed
52. Davies MA, Conley Y, Roth BL. Functional SNPs in Genes encoding the 5-ht2a receptor modify the affinity and potency of several atypical antipsychotic drugs. Biol Res Nurs. 2010. doi:10.17/10980409358760 PubMed
53. Summary of Product Characteristics. Seroquel. eMC (the electronic Medicines Compendium) Web site. http://www.medicines.org.uk/EMC/medicine/2295/ SPC/SEROQUEL+25+mg%2c+100+mg%2c+150+mg%2c+200+mg%2c+300+mg+film-coated+tablets/. Accessed November 29, 2010.
54. Nemeroff CB, Kinkead B, Goldstein J. Quetiapine: Preclinical studies, pharmacokinetics, drug interactions, and dosing. J Clin Psychiatry. 2002;63(suppl 13):5-11. PubMed (Pubitemid 35471364)
55. Fabre LF Jr, Arvanitis L, Pultz J, et al. ICI 204,636, a novel, atypical antipsychotic: Early indication of safety and efficacy in patients with chronic and subchronic schizophrenia. Clin Ther. 1995;17(3):366-378. doi:10.1016/0149-2918(95)80102-2 PubMed
56. Wong JYM, Ewing BJ, Jaskiw G, et al. Multiple-dose pharmacokinetics of 'Seroquel' (ICI 204,636) in elderly schizophrenic patients. Eur Psychiatry. 1996;11(suppl 4):430s. doi:10.1016/0924-938(96)89417-X
57. Wong JYW, Ewing BJ, Fabre LF, et al. Multiple-dose pharmacokinetics of "Seroquel" (ICI 204,636) in schizophrenic men and women. Eur Psychiatry. 1996;11:429s-430s. doi:10.1016/0924-938(96)89416-8
58. Wong JYM, Ewing BJ, Thyrum PT, et al. Multiple-dose pharmacokinetics of 'Seroquel' (quetiapine) in schizophrenic men and women. Schizophr Res. 1997;24(1-2):200.
59. Küfferle B, Tauscher J, Asenbaum S, et al. IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol. Psychopharmacology (Berl). 1997;133(4):323-328. PubMed doi:10.107/s0213050409
60. Davis PC, Wong J, Gefvert O. Analysis and pharmacokinetics of quetiapine and two metabolites in human plasma using reversed-phase HPLC with ultraviolet and electrochemical detection. J Pharm Biomed Anal. 1999;20(1-2):271-282. PubMed doi:10.1016/S0731-7085(9)036-9
61. Kimko HC, Reele SS, Holford NH, et al. Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model. Clin Pharmacol Ther. 2000;68(5):568-577. doi:10.1067/mcp.20.10975 PubMed
62. Stephenson CM, Bigliani V, Jones HM, et al. Striatal and extra-striatal D(2)/D(3) dopamine receptor occupancy by quetiapine in vivo. [(123) I]-epidepride single photon emission tomography(SPET) study. Br J Psychiatry. 2000;177(5):408-415. doi:10.192/bjp.17.5.408 PubMed
63. Sachse J, Hartter S, Muller MJ, et al. Therapeutic drug monitoring of quetiapine. Psychopharmakotherapie. 2003;10:19-22. (Pubitemid 36249496)
64. Savasi I, Millson RC, Owen JA. Quetiapine blood level variability. Can J Psychiatry. 2002;47(1):94. PubMed
65. Rothenhofer S, Mehler-Wex C, Schupp U, et al. Therapeutic drug monitoring of quetiapine in child and adolescents. Pharmacopsychiatry. 2005;38:75.
66. Strakowski SM, Keck PE Jr, Wong YW, et al. The effect of multiple doses of cimetidine on the steady-state pharmacokinetics of quetiapine in men with selected psychotic disorders. J Clin Psychopharmacol. 2002;22(2):201-205. doi:10.1097/04714-202040-015 PubMed (Pubitemid 34289396)
67. Potkin SG, Thyrum PT, Alva G, et al; Pharmacokinetic Study Group. Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine. J Clin Psychopharmacol. 2002;22(2):174-182. doi:10.1097/04714-202040-01 PubMed (Pubitemid 34289392)
68. Li KY, Li X, Cheng ZN, et al. Effect of erythromycin on metabolism of quetiapine in Chinese suffering from schizophrenia. Eur J Clin Pharmacol. 2005;60(11):791-795. doi:10.107/s028-04-0853-x PubMed (Pubitemid 40394573)
69. Härtter S, Connemann B, Schönfeldt-Lecuona C, et al. Elevated quetiapine serum concentrations in a patient treated concomitantly with doxepin, lorazepam, and pantoprazole. J Clin Psychopharmacol. 2004;24(5):568-571. PubMed doi:10.1097/01.jcp.0139756.58092.d8
70. Köhnlein O, Lutz R, Schmauss M, et al. [Determining serum concentrations of the modern antipsychotic quetiapin: clinical relevance in therapeutic drug monitoring]. [Article in German] Psychiatr Prax. 2004;31(suppl 1):S175-S177. PubMed
71. Sachse J, Köller J, Härtter S, et al. Automated analysis of quetiapine and other antipsychotic drugs in human blood by high performance-liquid chromatography with column-switching and spectrophotometric detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2006;830(2):342-348. doi:10.1016/j.jchromb.205.1.032 PubMed (Pubitemid 43075471)
72. Winter HR, DeVane CL, Figueroa C, et al. Open-label steady-state pharmacokinetic drug interaction study on co-administered quetiapine fumarate and divalproex sodium in patients with schizophrenia, schizoaffective disorder, or bipolar disorder. Hum Psychopharmacol. 2007;22(7):469-476. doi:10.102/hup.869 PubMed (Pubitemid 47611302)
73. Schulz-Du Bois C, Schulz-Du Bois AC, Bewig B, et al. Major increase of quetiapine steady-state plasma concentration following co-state plasma concentration following co-administration of clarithromycin: confirmation of the pharmacokinetic interaction potential of quetiapine. Pharmacopsychiatry. 2008;41(6):258-259. doi:10.105/s-028-1082071 PubMed
74. Catafau AM, Penengo MM, Nucci G, et al; Barcelona Clinical Imaging in Psychiatry Group. Pharmacokinetics and time-course of D(2) receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients. J Psychopharmacol. 2008;22(8):882-894. doi:10.17/02698107083810 PubMed